As a bronchoscopic treatment for severe #COPD/#emphysema, the Zephyr Valves design accommodates a variety of airway sizes and shapes and is specially designed to adapt to the dynamic conditions of the airway. Learn more: https://bit.ly/4fc6RRH #ZephyrValvebyPulmonx #Pulmonology
Pulmonx Corporation
Medical Equipment Manufacturing
Redwood City, CA 15,730 followers
Improving Breathing and Quality of Life for Emphysema and Advanced COPD Patients
About us
Pulmonx has developed the Zephyr Endobronchial Valve, a minimally invasive treatment for COPD/emphysema. The one-time procedure is done by bronchoscopy and requires no cutting or incisions. During the procedure, on average 4 tiny valves are placed in the airways to block off the diseased parts of the lung which allows trapped air to escape until the lobe is reduced. Reducing hyperinflation allows the healthier parts of the lungs to expand and take in more air. This results in patients being able to breathe easier and have less shortness of breath.1 Complications of the Zephyr Endobronchial Valve treatment can include but are not limited to pneumothorax, worsening of COPD symptoms, hemoptysis, pneumonia, dyspnea and, in rare cases, death.1 1. Criner G et al AM J Resp Crit Care Med 2018, Published on 22-May-2018 as 10.1164/rccm.201803-0590OC Brief Statement: The Pulmonx Zephyr® Endobronchial Valves are implantable bronchial valves indicated for the bronchoscopic treatment of adult patients with hyperinflation associated with severe emphysema in regions of the lung that have little to no collateral ventilation. The Zephyr Valve is contraindicated for: Patients for whom bronchoscopic procedures are contraindicated; those with evidence of active pulmonary infection; known allergies to Nitinol (nickel-titanium) or its constituent metals (nickel or titanium); known allergies to silicone, or with large bullae encompassing greater than 30% of either lung; Patients who have not quit smoking. The Zephyr Valve should be used with caution and only after careful consideration in treating patients with: Prior lung transplant, LVRS, median sternotomy, or lobectomy; Congestive heart failure or recent myocardial infarction; FEV1 <15% of predicted value. Use is restricted to a trained physician. Prior to use, please reference the Zephyr Endobronchial Valve System Instructions for more information on indications, contraindications, warnings, all precautions, and adverse events.
- Website
-
http://www.Pulmonx.com
External link for Pulmonx Corporation
- Industry
- Medical Equipment Manufacturing
- Company size
- 201-500 employees
- Headquarters
- Redwood City, CA
- Type
- Privately Held
- Specialties
- Medical Device, Interventional Pulmonology, Emphysema Treatment, and Endobronchial Valve Therapy
Locations
-
Primary
700 Chesapeake Drive,
Redwood City, CA 94063, US
-
Rue de la Treille 4
Neuchâtel, 2000, CH
Employees at Pulmonx Corporation
Updates
-
A single-center, non-randomized, prospective study examined the effects of Bronchoscopic Lung Volume Reduction (BLVR) on cardiac function in 24 patients. Patients with severe #COPD/#emphysema without a history of cardiovascular disease who were treated with Zephyr Valves experienced significant improvements in cardiac preload, myocardial contractility, and cardiac output with no changes in pulmonary artery pressures.* Read more: https://bit.ly/3ESBsTD #BLVR #Bronchoscopy #MedDevice #Pulmonology
-
In the latest Medscape clinician handbook and CME activity, learn how to identify potential candidates for endobronchial valve treatment and how it can improve quality of life for severe COPD/emphysema patients. https://bit.ly/3THFGp3 #Medscape #BLVR #Pulmonology
-
I was fortunate to witness a groundbreaking milestone in pulmonary care with a team of extraordinary people! Dr. Gerard Criner has treated the first CV+ patient in the US under the CONVERT II Trial using the AeriSeal System (The AeriSeal System is an investigational device and not available for commercial sale in the United States). This innovative approach targets and treats fissural defects that cause collateral ventilation between lung lobes. Our focus at Pulmonx is on developing and testing innovative medical technologies to improve life for patients with severe lung disease. With the ability to seal these fissures, we hope to extend the benefits of Zephyr Valves to many more patients with severe COPD/emphysema. This achievement marks a significant step forward in pulmonary care. It showcases the potential of the AeriSeal System to transform treatment for patients who previously had limited options. Pulmonx remains committed to pioneering advances in medical technology. Our goal is to offer new hope and improved quality of life to those battling severe lung conditions. Stay tuned for more updates as we continue to push the boundaries of what's possible in pulmonary care. Temple University Hospital Young Lee Lou Browne Anna K. Gawlicka, PhD MBA Sami E.
-
The Zephyr Valve may lead to significant, sustained improvement in breathing for people who have severe #COPD/#emphysema. During a minimally invasive procedure, the valves are placed in the lungs to help reduce hyperinflation in patients with heterogeneous or homogenous emphysema. See if the Zephyr Valve is right for your patients: https://bit.ly/34GAbwQ #COPDAwareness #MedTech #Pulmonology #BreatheBetter #Pulmonary
-
Zephyr Valves are a standard of care treatment option for patients with severe #COPD/#emphysema. Learn more: https://bit.ly/3zC3dQF #COPDSupport #Lung #Pulmonology #Respiratory #LungHealth #BreatheBetter
Zephyr Valves for Severe COPD/emphysema
-
Studies show that Zephyr Valves improve health status and quality of life for patients with severe #COPD/#emphysema. With an increase in lung function and decrease of trapped air, the Zephyr Valves may help your patients get back to their favorite daily activities. Learn more: https://bit.ly/46YYmWe #MedicalDevice #ZephyrByPulmonx #MedTech #Bronchology
-
With a GOLD 2023: Level A Evidence rating, the Zephyr Valves are a viable treatment for patients with severe #COPD/#emphysema. Learn more about the Zephyr Valves and patient selection here: https://bit.ly/3VSFqEW
-
BLVR impact on cardiac function: A single-center, non-randomized, prospective study showed significant clinical improvements in cardiac preload, myocardial contractility and cardiac output for patients with severe #COPD/#emphysema without a history of cardiovascular disease.* Read more: https://bit.ly/3ESBsTD #BLVR #Bronchoscopy #MedDevice #Pulmonology
-
Pulmonx Corporation reposted this
Our 2nd Annual Advanced Clinical Summit was a tremendous success! This year’s event gathered dedicated professionals, passionate about advancing patient care in the field of BLVR. Attendees participated in a comprehensive curriculum designed to identify patients most likely to benefit from our interventions, build efficient patient pathways, and engage administration to secure necessary resources. It was incredibly exciting to witness the camaraderie and shared purpose as we work together to build the next generation of BLVR programs. I am truly humbled to collaborate with the exceptional physicians and staff at Zephyr Valve treating centers, united in our mission to fight for every breath so that COPD patients don’t have to. Together, we are making a difference, one breath at a time! Bobby Mahajan MD, FCCP, DAABIP Medical Director, Inova Interventional Pulmonology Jonathan Kurman Deborah Stahlnecker Bunn Jill Josiebeth Rivera Melendez Ahmed Khan Mark Vollenweider Narinder Singh Shargill, PhD #AdvancedClinicalSummit #BLVR #COPD #ZephyrValve #HealthcareInnovation #ForEveryBreath